REG Iα is a reliable marker of chemoradiosensitivity in squamous cell esophageal cancer patients
REG Iα is a reliable marker of chemoradiosensitivity in squamous cell esophageal cancer patients
复制标题
DOI：
10.1245/s10434-008-9810-8
复制
发表时间：
2008-04-01
影响因子：
3.7
通讯作者：
Ogawa, Jun-Ichi
中科院分区：
文献类型：
--
作者：
Hayashi, Kaori;Motoyama, Satoru;Ogawa, Jun-Ichi
背景资料：长期以来，人们一直在寻找一种可靠的放化疗敏感性标志物，以实现胸段鳞状细胞食管癌的适当和个体化治疗。我们调查是否再生基因（REG）I α是这样一个marker.Methods：我们评估了未经治疗的内镜活检标本中的REG I α的表达，并研究了REG I α表达与明确的放化疗和预后的临床反应之间的相关性。我们还研究了REG I α的表达在切除肿瘤和预后的患者接受食管切除术的胸鳞状细胞食管cancer.Results：在42例患者治疗与明确的放化疗，8的23个REG I阳性患者（35%）显示完全响应放化疗，而只有一个19个REG I阴性的患者这样做。REG I阳性患者的生存率明显高于REG I阴性患者。对于76例手术治疗的患者，有没有明显的差异，在生存率之间的REG I阳性和REG I阴性patients.Conclusions：REG I α表达在鳞状细胞食管癌可能是一个可靠的标记化疗放射敏感性。我们期望这将使我们能够为晚期食管鳞状细胞癌患者提供更合适和个性化的治疗。
Background: A reliable marker of chemoradiosensitivity that would enable appropriate and individualized treatment of thoracic squamous cell esophageal cancer has long been sought. We investigated whether regenerating gene (REG) I alpha is such a marker.Methods: We assessed expression of REG I alpha in untreated endoscopic biopsy specimens and examined the correlation between REG I alpha expression and the clinical responses to definitive chemoradiotherapy and prognosis. We also examined the relationship between REG I alpha expression in the resected tumor and the prognosis of patients who received esophagectomy for thoracic squamous cell esophageal cancer.Results: Among the 42 patients treated with definitive chemoradiotherapy, 8 of the 23 REG I-positive patients (35%) showed complete responses to chemoradiotherapy, while only one of the 19 REG I-negative patients did so. The survival rate among the REG I-positive patients was significantly better than among the REG I-negative patients. For the 76 patients treated surgically, there was no significant difference in the survival rates among the REG I-positive and REG I-negative patients.Conclusions: REG I alpha expression in squamous cell esophageal carcinoma may be a reliable marker of chemoradiosensitivity. We anticipate that it will enable us to provide more appropriate and individualized treatment to patients of advanced esophageal squamous cell carcinoma.